Benzamide modulators of metabotropic glutamate receptors
View Patent ↗The present invention is directed to compounds which are allosteric modulators of metabotropic glutamate receptors, including the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
1. A compound of the formula I:
wherein:
R 1 is selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) C 1-6 alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,
(4) —OC 1-6 alkyl,
(5) —S(O) m —C 1-6 alkyl, wherein m is selected from 0, 1 and 2,
(6) —CO 2 R 9 , wherein R 9 is independently selected from:
(a) hydrogen,
(b) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,
(c) benzyl, and
(d) phenyl,
(7) —NR 10 R 11 , wherein R 10 and R 11 are independently selected from:
(a) hydrogen,
(b) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,
(c) —C 5-6 cycloalkyl,
(d) benzyl,
(e) phenyl,
(f) —S(O) 2 —C 1-6 alkyl,
(g) —S(O) 2 -benzyl, and
(h) —S(O) 2 -phenyl,
(8) —S(O) 2 —NR 10 R 11 ,
(9) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
(a) —C 1-6 alkyl,
(b) —O—C 1-6 alkyl,
(c) halo,
(d) hydroxy,
(e) trifluoromethyl, and
(f) —OCF 3 ;
R 3 is selected from the group consisting of:
(1) C 1-6 alkyl, which is substituted with halogen, hydroxyl or phenyl,
(2) C 3-7 cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
(3) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
(a) —C 1-6 alkyl, which is unsubstituted or substituted with —NR 10 R 11 ,
(b) —O—C 1-6 alkyl,
(c) halo,
(d) hydroxy,
(e) trifluoromethyl,
(f) —OCF 3 ;
(g) —CO 2 R 9 ,
(h) —NR 10 R 11 ,
(i) —C(O)NR 10 R 11 , and
(j) —NO 2 ,
(4) heterocycle, wherein heterocycle is selected from:
benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof, which is unsubstituted or substituted with one or more substituents independently selected from:
(a) —C 1-6 alkyl,
(b) —O—C 1-6 alkyl,
(c) halo,
(d) hydroxy,
(e) phenyl,
(f) trifluoromethyl,
(g) —OCF 3 ;
(h) —CO 2 R 9 ,
(i) —NR 10 R 11 , and
(j) —CONR 10 R 11 ;
R 4 is selected from the group consisting of:
(1) C 1-6 alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,
(2) C 3-7 cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
(3) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
(a) —C 1-6 alkyl,
(b) —O—C 1-6 alkyl,
(c) halo,
(d) hydroxy,
(e) trifluoromethyl,
(f) —OCF 3 ,
(g) —CO 2 R 9 ,
(h) —NR 10 R 11 ,
(i) —CONR 10 R 11 , and
(j) —NO 2 ;
(4) heterocycle, wherein heterocycle is selected from:
benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof, which is unsubstituted or substituted with one or more substituents independently selected from:
(a) —C 1-6 alkyl,
(b) —O—C 1-6 alkyl,
(c) halo,
(d) hydroxy,
(e) phenyl,
(f) trifluoromethyl,
(g) —OCF 3 ,
(h) —CO 2 R 9 ,
(i) —NR 10 R 11 , and
(j) —CONR 10 R 11 ;
or wherein R 4 and R 5 are joined together to form a phthalimidyl, succinimidyl or glutamidyl ring, which is unsubstituted or substituted with one or more substituents independently selected from the definitions of R 2 ;
R 2 is selected from the group consisting of:
(1) hydrogen,
(2) —C 1-6 alkyl,
(3) —O—C 1-6 alkyl,
(4) halo,
(5) hydroxyl,
(6) —NO 2 , and
(7) phenyl;
R 5 and R 6 are independently selected from the group consisting of:
(1) hydrogen, and
(2) C 1-6 alkyl;
n is an integer selected from 1, 2 and 3;
with the proviso that the compound of formula I is not:
N-[4-chloro-2-[(1,3-dihydro- 1,3-dioxo-2H-isoindol-2-yl)methyl]phenyl]-acetamide,
N-[2-[(1,3-dihydro- 1,3-dioxo-2H-isoindol-2-yl)methyl]-4-methylphenyl]-acetamide, or
N-[2-[(1,3-dihydro- 1,3-dioxo-2H-isoindol-2-yl)methyl]phenyl]-acetamide;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 of the formula Ia:
wherein
R 2 is selected from the group consisting of:
(1) hydrogen,
(2) —C 1-6 alkyl,
(3) —O—C 1-6 alkyl,
(4) halo,
(5) hydroxy,
(6) —NO 2 , and
(7) phenyl;
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 of the formula Ib:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 of the formula Ic:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 of the formula Id:
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 of the formula Ie:
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 of the formula If:
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 wherein R 1 is hydrogen.
9. The compound of claim 1 wherein R 2 is halo.
10. The compound of claim 9 wherein R 2 is fluoro.
11. The compound of claim 9 wherein R 2 is chloro.
12. The compound of claim 9 wherein R 2 is bromo.
13. The compound of claim 1 wherein R 2 is methyl.
14. The compound of claim 1 wherein R 3 is phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
(a) —C 1-6 alkyl,
(b) —O—C 1-6 alkyl,
(c) halo,
(d) hydroxy,
(e) trifluoromethyl,
(f) —OCF 3 ;
(g) —CO 2 —C 1-6 alkyl,
(h) —NH 2 ,
(i) —NH—C 1-6 alkyl,
(j) —CONH 2 , and
(k) —CONH—C 1-6 alkyl.
15. The compound of claim 14 wherein R 3 is phenyl, which is unsubstituted or substituted with hydroxy, halo, —CONHC 1-6 alkyl or —CO 2 C 1-6 alkyl.
16. The compound of claim 1 wherein R 3 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperazinyl, furanyl or thienyl.
17. The compound of claim 1 wherein R 4 and R 5 are joined together to form a phthalimidyl ring.
18. The compound of claim 1 wherein R 5 is hydrogen or C 1-6 alkyl.
19. The compound of claim 1 wherein R 6 is hydrogen.
20. The compound of claim 1 wherein n is 1.
21. A compound which is selected from the group consisting of:
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyrimidine-2-carboxamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide;
2-[({2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-fluorophenyl}amino)carbonyl]phenyl;
N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-fluorophenyl}-2-hydroxybenzamide;
2-chloro-N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-fluorophenyl}benzamide;
N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-fluorophenyl}-2-fluorobenzamide;
N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-fluorophenyl}benzamide;
N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-fluorophenyl}-3,5-difluorobenzamide;
N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-3-methoxybenzamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-methylbenzamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-furamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-5-methylisoxazole-3-carboxamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}cyclohexanecarboxamide;
N-{5-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}cyclohexanecarboxamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-1-methyl-1H-imidazole-2-carboxamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-1,3-thiazole-4-carboxamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-3-hydroxypyridine-2-carboxamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}imidazo[2,1-b][1,3]thiazole-6-carboxamide;
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-1,2,5-thiadiazole-3-carboxamide;
N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-4-methoxyphenyl}pyridine-2-carboxamide;
N-{4-bromo-2-[(4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{4-chloro-2-[(2,5-dioxo-3-phenyl-2,5-dihydro-1H-pyrrol-1-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{4-chloro-2-[(4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{4-chloro-2-[(5,6-dimethyl-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{4-chloro-2-[(5-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{4-chloro-2-[(5-ethoxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{5-bromo-3-[(5,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]pyridin-2-yl}pyridine-2-carboxamide;
N-{4-chloro-2-[(5-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{4-bromo-2-[(5-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{4-bromo-2-[(5-ethoxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{4-bromo-2-[(5,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{4-bromo-2-[(4,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{2-[(4,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-4-fluorophenyl}pyridine-2-carboxamide;
N-{2-[(5,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-4-fluorophenyl}pyridine-2-carboxamide;
N-{4-fluoro-2-[(5-nitro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{4-bromo-2-[(4-methyl-1,3-dioxo-3,4,5,6-tetrahydrocyclopenta[c]-pyrrol-2(1H)-yl)methyl]phenyl}pyridine-2-carboxamide;
N-{5-bromo-2-[(pyridin-2-ylcarbonyl)amino]benzyl}pyridine-2-carboxamide;
N-(4-bromo-2-{[(2-fluorobenzoyl)amino]methyl}phenyl)pyridine-2-carboxamide;
N-{5-bromo-2-[(pyridin-2-ylcarbonyl)amino]benzyl}pyridine-2-carboxamide;
N-[4-bromo-2-({[2-(trifluoromethyl)benzoyl]amino}methyl)phenyl]-pyridine-2-carboxamide;
N-(4-chloro-2-{[(3,5-dichlorobenzoyl)(ethyl)amino]methyl}phenyl)-pyridine-2-carboxamide;
N-(2-{[(4-butoxybenzoyl)(ethyl)amino]methyl}-4-chlorophenyl)-pyridine-2-carboxamide;
N-(4-chloro-2-{[(3,5-dimethoxybenzoyl)(ethyl)amino]methyl}phenyl)pyridine-2-carboxamide;
N-(4-chloro-2-{[(3,4-dichlorobenzoyl)(ethyl)amino]methyl}phenyl)pyridine-2-carboxamide;
N-(4-chloro-2-{[(3,5-dichlorobenzoyl)(isobutyl)amino]methyl}phenyl)pyridine-2-carboxamide;
N-(4-chloro-2-{[(3,5-dimethoxybenzoyl)(isobutyl)amino]methyl}phenyl)pyridine-2-carboxamide;
N-{5-fluoro-2-[(pyridin-2-ylcarbonyl)amino]benzyl}quinoxaline-2-carboxamide;
N-(2-{[(4-butoxybenzoyl)amino]methyl}-4-fluorophenyl)pyridine-2-carboxamide;
N-(4-bromo-2-{[(3-methoxybenzoyl)(methyl)amino]methyl}phenyl)pyridine-2-carboxamide;
N-(4-chloro-2-{[(3,5-dichlorobenzoyl)(methyl)amino]methyl}phenyl)pyridine-2-carboxamide;
N-(2-{[[3,5-bis(trifluoromethyl)benzoyl](methyl)amino]methyl}-4-chlorophenyl)pyridine-2-carboxamide;
N-[4-chloro-2-({(3,5-dichlorobenzoyl) [2-(dimethylamino)ethyl]amino}methyl)-phenyl]pyridine-2-carboxamide;
N-[2-(benzoylamino)-5-bromobenzyl]-N,3,5-trimethylbenzamide;
N-(4-bromo-2-{[(3,5-dichlorobenzoyl)(methyl)amino]methyl}-phenyl)pyridine-2-carboxamide;
N-(4-bromo-2-{[(3,4-difluorobenzoyl)(methyl)amino]methyl}phenyl)-pyridine-2-carboxamide;
N-(4-bromo-2-{[(2,4-difluorobenzoyl)(methyl)amino]methyl}phenyl)-pyridine-2-carboxamide;
N-(4-bromo-2-{[(3,4-dichlorobenzoyl)(methyl)amino]methyl}phenyl)-pyridine-2-carboxamide;
N-[4-chloro-2-({methyl[2-(trifluoromethyl)benzoyl]amino}methyl)-phenyl]pyridine-2-carboxamide;
N-(4-chloro-2-{[(3,4-dichlorobenzoyl)(methyl)amino]methyl}-phenyl)pyridine-2-carboxamide;
or a pharmaceutically acceptable salt thereof.
22. A compound which is:
or a pharmaceutically acceptable salt thereof.
23. A pharmaceutical composition which comprises an insert carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.
24. A pharmaceutical composition which comprises an inert carrier and a compound of claim 21 or a pharmaceutically acceptable salt thereof.
25. A method for potentiation or inhibition of metabotropic glutamate receptor activity in a mammal which comprises the administration of an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
26. A method for treating, controlling, or reducing the risk of schizophrenia in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.